Report Detail
Global Hospital-Acquired Pneumonia (HAP) Drugs Market Insights, Forecast to 2025
- RnM3480379 |
- 31 May, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.
One driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
The global Hospital-Acquired Pneumonia (HAP) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hospital-Acquired Pneumonia (HAP) Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Hospital-Acquired Pneumonia (HAP) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hospital-Acquired Pneumonia (HAP) Drugs in these regions.
This research report categorizes the global Hospital-Acquired Pneumonia (HAP) Drugs market by top players/brands, region, type and end user. This report also studies the global Hospital-Acquired Pneumonia (HAP) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Merck
Mylan
Novartis
Teva Pharmaceutical Industries
AstraZeneca
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
Market size by Product
Antibacterial
Antiviral
Antifungal
Market size by End User
Hospitals
Clinics
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Hospital-Acquired Pneumonia (HAP) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hospital-Acquired Pneumonia (HAP) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hospital-Acquired Pneumonia (HAP) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hospital-Acquired Pneumonia (HAP) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Hospital-Acquired Pneumonia (HAP) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hospital-Acquired Pneumonia (HAP) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Hospital-Acquired Pneumonia (HAP) Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by Product
- 1.4.2 Antibacterial
- 1.4.3 Antiviral
- 1.4.4 Antifungal
- 1.5 Market by End User
- 1.5.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size
- 2.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue 2014-2025
- 2.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales 2014-2025
- 2.2 Hospital-Acquired Pneumonia (HAP) Drugs Growth Rate by Regions
- 2.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Regions
- 2.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers
- 3.1.1 Hospital-Acquired Pneumonia (HAP) Drugs Sales by Manufacturers
- 3.1.2 Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers
- 3.2.1 Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Hospital-Acquired Pneumonia (HAP) Drugs Price by Manufacturers
- 3.4 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Hospital-Acquired Pneumonia (HAP) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Hospital-Acquired Pneumonia (HAP) Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Hospital-Acquired Pneumonia (HAP) Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Product
- 4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Product
- 4.3 Hospital-Acquired Pneumonia (HAP) Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Breakdown Data by End User
6 North America
- 6.1 North America Hospital-Acquired Pneumonia (HAP) Drugs by Countries
- 6.1.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Countries
- 6.1.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Hospital-Acquired Pneumonia (HAP) Drugs by Product
- 6.3 North America Hospital-Acquired Pneumonia (HAP) Drugs by End User
7 Europe
- 7.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs by Countries
- 7.1.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Countries
- 7.1.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs by Product
- 7.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs by Countries
- 8.1.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Countries
- 8.1.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs by Product
- 8.3 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs by End User
9 Central & South America
- 9.1 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs by Countries
- 9.1.1 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Countries
- 9.1.2 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs by Product
- 9.3 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs by Countries
- 10.1.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Countries
- 10.1.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs by Product
- 10.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.1.5 Pfizer Recent Development
- 11.2 Merck
- 11.2.1 Merck Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.2.5 Merck Recent Development
- 11.3 Mylan
- 11.3.1 Mylan Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.3.5 Mylan Recent Development
- 11.4 Novartis
- 11.4.1 Novartis Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.4.5 Novartis Recent Development
- 11.5 Teva Pharmaceutical Industries
- 11.5.1 Teva Pharmaceutical Industries Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.5.5 Teva Pharmaceutical Industries Recent Development
- 11.6 AstraZeneca
- 11.6.1 AstraZeneca Company Details
- 11.6.2 Company Business Overview
- 11.6.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.6.5 AstraZeneca Recent Development
- 11.7 Shinogi
- 11.7.1 Shinogi Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.7.5 Shinogi Recent Development
- 11.8 Sun Pharmaceutical Industries
- 11.8.1 Sun Pharmaceutical Industries Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.8.5 Sun Pharmaceutical Industries Recent Development
- 11.9 The Medicines Company
- 11.9.1 The Medicines Company Company Details
- 11.9.2 Company Business Overview
- 11.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.9.5 The Medicines Company Recent Development
- 11.10 Theravance Biopharma
- 11.10.1 Theravance Biopharma Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Products Offered
- 11.10.5 Theravance Biopharma Recent Development
12 Future Forecast
- 12.1 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by Regions
- 12.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by Product
- 12.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Forecast by Product 2019-2025
- 12.3 Hospital-Acquired Pneumonia (HAP) Drugs Market Forecast by End User
- 12.4 North America Hospital-Acquired Pneumonia (HAP) Drugs Forecast
- 12.5 Europe Hospital-Acquired Pneumonia (HAP) Drugs Forecast
- 12.6 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Forecast
- 12.7 Central & South America Hospital-Acquired Pneumonia (HAP) Drugs Forecast
- 12.8 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Hospital-Acquired Pneumonia (HAP) Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Hospital-Acquired Pneumonia (HAP) Drugs . Industry analysis & Market Report on Hospital-Acquired Pneumonia (HAP) Drugs is a syndicated market report, published as Global Hospital-Acquired Pneumonia (HAP) Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Hospital-Acquired Pneumonia (HAP) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
